Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Olema Pharmaceuticals (OLMA) Liabilities and Shareholders Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Liabilities and Shareholders Equity data on record, last reported at $530.6 million in Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 29.54% to $530.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.8 billion, a 33.69% increase, with the full-year FY2025 number at $533.4 million, up 18.28% from a year prior.
  • Liabilities and Shareholders Equity reached $530.6 million in Q1 2026 per OLMA's latest filing, down from $533.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for OLMA hit a ceiling of $533.4 million in Q4 2025 and a floor of $177.6 million in Q2 2023.
  • A 5-year average of $313.3 million and a median of $276.9 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 29.43% in 2023, then soared 62.84% in 2024.
  • Tracing OLMA's Liabilities and Shareholders Equity over 5 years: stood at $215.6 million in 2022, then increased by 28.43% to $276.9 million in 2023, then soared by 62.84% to $451.0 million in 2024, then rose by 18.28% to $533.4 million in 2025, then decreased by 0.52% to $530.6 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for OLMA at $530.6 million in Q1 2026, $533.4 million in Q4 2025, and $352.5 million in Q3 2025.